12th week of 2020 patent applcation highlights part 11 |
Patent application number | Title | Published |
20200085954 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T | 2020-03-19 |
20200085955 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T | 2020-03-19 |
20200085956 | NOVEL ANTIOXIDANTS FOR COSMETICS AND PHARMACEUTICAL COMPOSITIONS CONTAINING GLYCEROL ALKYL ETHERS - A composition containing a glycerol alkyl ether of the general formula | 2020-03-19 |
20200085957 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS - The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes. | 2020-03-19 |
20200085958 | BIODEGRADABLE DRUG DELIVERY FOR HYDROPHOBIC COMPOSITIONS - A biodegradable drug delivery compositions comprising a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as at least one pharmaceutically active principle or hydrophobic active principle such as medroxyprogesterone acetate, levonorgestrel, cyclosporine, progesterone or bupivacaine is disclosed. | 2020-03-19 |
20200085959 | Cannabinoid and Terpene-Infused Topical Cream - The present invention discloses a topical composition comprising terpene blend and cannabidiol (CBD) or a derivative thereof, useful for managing pain, the treatment or prevention of inflammatory skin disorders, and treatment methods thereof. The composition includes 2-pyrrolidone-5-carboxylic acid and a blend of antioxidants to optimize tissue health. | 2020-03-19 |
20200085960 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF - Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer. | 2020-03-19 |
20200085962 | DENDRIMER CONJUGATES FOR COATING CELLS - The present invention provides dendrimer conjugates. The present invention provides a composition comprising a dendrimer conjugate and a cell, such as a cell covered with dendrimer conjugates, in which dendrimer conjugates home the cell to a target tissue. | 2020-03-19 |
20200085963 | CELL PENETRATING PROTEIN ADAPTOR MOLECULES AND THEIR APPLICATION IN RESEARCH AND MEDICINE - Cell penetrating peptides (CPPs) are established as a strategy to move cargoes into the interior of eukaryotic cells by engaging import machinery on the cell surface. In most cases the CPP is covalently linked to the cargo; it is common to express cargo proteins with a CPP extension. In some experiments a non-specific interactions (e.g., hydrophobic interactions) have been used to form CPP-cargo complexes, but this has numerous drawbacks. Transport is less efficient and the lack of specificity means that other macromolecules in the medium will also be internalized. This application describes the use of specific CPP labeled adaptor proteins that can be used to move a wide variety of cargoes into the cell interior. The prototype adaptor protein is calmodulin; it is small, stable and easily produced, and binds short (17 amino acid) targets with high affinity in the presence of calcium. A cargo produced with a calmodulin binding tag can be internalized efficiently by CPP tagged calmodulin. Because calcium in the cell interior is typically kept low, CPP-calmodulin releases cargoes inside the cell. The calmodulin binding tag can be used to efficiently purify target proteins by affinity chromatography. | 2020-03-19 |
20200085964 | Noncrushable Pill Formulations - Non-crushable pill formulations and methods of using the formulations are disclosed. A non-crushable pill formulation for preventing unintended use of a drug, comprising a polymer, the polymer forming a polymer backbone of the complex; cross-linkers, the cross-linkers connecting the polymer backbone through covalently bonding to form at least one inner cavity within the complex; and the drug, the drug being trapped either covalently or non-covalently in the at least one inner cavity within the complex, wherein the drug is protected from releasing outside of the complex. | 2020-03-19 |
20200085965 | PYRROLOBENZODIAZEPINE PRODRUGS AND ANTIBODY CONJUGATES THEREOF - The invention relates generally to pyrrolobenzodiazepine monomer and dimer prodrugs having a glutathione-activated disulfide prodrug moiety, a DT-diaphorase-activated quinone prodrug moiety or a reactive oxygen species-activated aryl boronic acid or aryl boronic ester prodrug moiety. The invention further relates to pyrrolobenzodiazepine prodrug dimer-antibody conjugates. | 2020-03-19 |
20200085966 | GLUCOSE OXIDASE-NANOPARTICLE BIOCONJUGATES FOR CANCER TREATMENT AND USES THEREOF - Bioconjugates and methods of making bioconjugates are provided, wherein the bioconjugates comprise glucose oxidase and nanoparticles that can kill tumor cells. For example, glucose oxidase-iron oxide bioconjugates can produce reactive oxygen species from blood glucose, causing cell death. The use of superparamagnetic iron oxide nanoparticles can provide magnetic resonance imaging guidance to facilitate imaging-guided drug delivery and combine diagnostics with therapy. | 2020-03-19 |
20200085967 | TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER - The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject. | 2020-03-19 |
20200085968 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to Trop-2 or CEACAM5 and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the immunoconjugate is effective to treat cancers that are refractory to or relapsed from irinotecan. | 2020-03-19 |
20200085969 | PLANT VIRUS PARTICLES FOR DELIVERY OF ANTIMITOTIC AGENTS - Anti-lymphoma plant virus particles are described. The anti-lymphoma plant virus particles include a filamentous or rod-shaped plant virus particle linked to an antimitotic agent. A therapeutically effective amount of an anti-lymphoma plant virus particle can be administered to a subject to provide a method of treating lymphoma. | 2020-03-19 |
20200085970 | NANORESERVOIRS - Nanoreservoirs and uses thereof, in particular the use of nanoreservoirs to coat a surface of a medical device, biomaterial or bioprosthetic. | 2020-03-19 |
20200085971 | METHODS AND COMPOSITIONS FOR MODULATION OF IMMUNE CELLS - The invention features a hydrogel complex that can bind to and modulate a desired immune cell, e.g., T cell, population. In certain embodiments, the complex can be dissolved, and thus dissociated from its targeted cell, representing a safe and efficient approach for processing immune cells, e.g., T cells for clinical use. The invention also provides methods and apparatus for synthesizing hydrogel complexes, as well as methods of using the complexes to generate expanded immune cell, e.g., T cell, populations as part of adoptive immune cell, e.g., T cell, therapy systems. | 2020-03-19 |
20200085972 | ENGINEERED LIPOSOMES AS CANCER-TARGETED THERAPEUTICS - The disclosure provides liposomes (e.g., cancer-targeting liposomes) with ligands (e.g., EGFR ligands and ICAM-1 ligands) conjugated to liposome surfaces. In some embodiments, the molecular ratio of different ligands complement the relative molecular density (i.e., ratio) of overexpressed protein on the surface of a cell targeted by the liposome (e.g., cancer cell). | 2020-03-19 |
20200085973 | LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY - Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies. | 2020-03-19 |
20200085974 | RNA Formulation for Immunotherapy - The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA. | 2020-03-19 |
20200085975 | GENE THERAPY FOR TREATING HEMOPHILIA A - Compositions and regimens useful in treating hemophilia A are provided. The compositions include recombinant adeno-associated virus (rAAV) with a transthyretin enhancer and promoter driving expression of a human Factor VIII. | 2020-03-19 |
20200085976 | IR DYES FOR FLUORESCENCE IMAGING - A method for organ imaging, comprising: administering to a subject a diagnostic effective amount of 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-phenoxycyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate or 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-(4-sulfonatophenoxy)cyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate. In one embodiment, the organ includes one or more of kidney, bladder, liver, gall bladder, spleen, intestine, heart, lungs and muscle. | 2020-03-19 |
20200085977 | DIAGNOSTIC USAGES OF SHORT-LIVED RADIOPHARMACEUTICALS - The present invention relates to the use of radiopharmaceuticals having a radioactive half-life of less than 21 minutes, such as oxygen-15 labeled water (H | 2020-03-19 |
20200085978 | COMPOSITION FOR CROSS TALK BETWEEN ESTROGEN RECEPTORS AND CANNABIONOID RECEPTORS - A composition for cross talk between estrogen receptors and cannabinoid receptors including a chelator and a receptor ligand is provided. A method of synthesizing the composition is also provided, and the composition may be further prepared in pharmaceutical formulations or kits for therapy or molecular imaging. | 2020-03-19 |
20200085979 | PRECISION MEDICINE THERANOSTICS AND DIAGNOSTICS A COMBINATION THEREOF - The component ‘drug’ new molecule for combining metals into complexes through a ring structure (DOTA) or linear structure, and a radionuclidic component, and chelating agent wherein embodiments may include a companion diagnostic, and in which embodiments further include anti-integrin precision medicines for cancers expressing αvβ3 and αvβ5 integrins, second component for combining metals into complexes through a ring or linear structure, and one or more radionuclidic components, a chelating agent for diagnosis and/or therapy (theranostic) in which the embodiments further include a anti-integrin peptidomimetic for precision medicine for cancers expressing αvβ3 and αvβ5 integrins. | 2020-03-19 |
20200085980 | CASPASE-3-TRIGGERED MOLECULAR SELF-ASSEMBLING PET PROBES AND USES THEREOF - Embodiments of the synthesis, radiolabeling and biological applications of an activatable tracer that undergoes intramolecular cyclization and aggregation upon activation by cleavage of a blocking moiety are provided. The probes of the disclosure allow for target-controlled self-assembly of small molecules in living subjects for imaging and drug delivery. The aggregated nanoprobes of the disclosure may be detectable optically, by PET detection, magnetic resonance imaging, and the like depending on the detectable reporter attached to the nanoprobe. | 2020-03-19 |
20200085981 | TUMOR TARGETED RADIONUCLIDE THERAPY AND MOLECULAR IMAGING OF HER2+ CANCERS AND OTHER NEOPLASMS - Methods and compositions for treating, diagnosing and staging cancers, in particular overexpressing the Human Epidermal growth factor Receptor 2 protein (HER2+) given rise to in breast, gastric, gastroesophageal, ovarian, pancreatic cancer and brain tumors, which may be metastatic to the brain or other site. More specifically, the invention provides for Targeted Radionuclide Therapy (TRNT) with a compound of the invention having a peptide that targets the HER2+ cells, a second component for combining metals into complexes through a ring structure (DOTA), and a third radioisotope component, Lu-177 and Ga-68, in which embodiments further include a companion diagnostic, and in which embodiments further include anti-integrin precision medicines for cancers expressing αvβ3 and αvβ5 integrins, HER2+, vascular endothelial growth factor, vitronectin, fibronectin, tenascin, reelin, kindlin and talin. TRNT may be administered alone or in combination with standard-of-care; an immunooncologic and/or chemotherapeutic, adjuvantly or neoadjuvantly. | 2020-03-19 |
20200085982 | POUCH WITH BREAKABLE SEAL - A wipe kit includes a pouch having a first compartment with a one-way valve coupled to an end thereof, a second compartment, and a frangible seal between the first and second compartments. The first compartment receives a liquid through the one-way valve and the second compartment contains a dry wipe. The frangible seal can be broken to permit liquid to flow from the first compartment onto the wipe in the second compartment. The deactivation wipe kit may be used in a clean room to deactivate most hazardous drugs on a work surface. | 2020-03-19 |
20200085983 | TARGETED SURFACE DISINFECTION SYSTEM WITH PULSED UV LIGHT - Embodiments of a targeted surface disinfection system are disclosed. The system includes a set of one or more UV lamps, a high voltage power supply for driving the lamps, a mobile carriage including a chassis supporting the set, an articulated head assembly including at least one UV lamp from the set, a vacuum pump, and a suction hose extending between the vacuum pump and the head assembly for dissipating heat generated by the at least one UV lamp. The system also includes a pulse configuration control unit for configuring an output of the high voltage power supply for driving the set to emit a UV radiant energy upon a target surface requiring disinfection, where the set of one or more UV lamps emits the UV radiant energy at a rate of at least 20 pulses per second. | 2020-03-19 |
20200085984 | APPARATUS, METHOD AND SYSTEM FOR SELECTIVELY AFFECTING AND/OR KILLING A VIRUS - Certain exemplary embodiments of the present disclosure can provide an apparatus and method for generating at least one radiation can be provided. The exemplary apparatus and/or method can selectively kill and/or affect at least one virus. For example, a radiation source first arrangement can be provided which is configured to generate at least one radiation having one or more wavelengths provided in a range of about 200 nanometers (nm) to about 230 nm, and at least one second arrangement can be provided which is configured to prevent the at least one radiation from having any wavelength that is outside of the range can be provided or which can be substantially harmful to cells of the body. | 2020-03-19 |
20200085985 | MULTIPLE CHAMBER DECONTAMINATION DEVICE WITH A STERILIZING SUBSTANCE - The present invention relates, in some embodiments thereof, to devices and methods for decontaminating a surface of one or more vessels. In some embodiments, the devices of the invention include a first and a second chamber wherein the first chamber configured to accommodate a sterilizing substance and is fluidly connected to the second chamber, the second chamber configured to connect at least one vessel and to receive the sterilizing substance from the first chamber, wherein upon transferring the sterilizing substance to the second chamber, the surface of the at least one vessel is decontaminated. | 2020-03-19 |
20200085986 | USE OF FLUORESCENT POLYMERS IN MARKING COMPOSITIONS FOR THE DIAGNOSTIC DETERMINATION OF CLEANING PERFORMANCE - The present invention generally relates to fluorescent marking compositions and their use to determine whether a surface has been cleaned. More particularly, the marking compositions comprise fluorescent polymers. | 2020-03-19 |
20200085987 | COMPOSITION FOR THE PREVENTION AND ELIMINATION OF ODORS - Articles can be provided with odor resistance by applying a dispersion of a halogenated heterocyclic N-halamine in an inert liquid carrier onto the surface of the article and allowing the inert liquid carrier to penetrate into it. The N-halamine accordingly becomes deposited on the surface of the article after the inert liquid carrier penetrates into the article. This method can be used to provide odor resistance to a variety of substrates, including garbage bags. It can also be used to deposit other functional particulates onto the surface of substrates having sufficient porosity to take up the vehicle. For instance, such functional particles can be oxidants that display antimicrobial and/or enzyme inhibitory efficacy or particles having toxin interaction potentials through oxidative degradation or adsorption of toxic substances in air and/or water, such as fluoride uptake by metal oxide microparticles. | 2020-03-19 |
20200085988 | Tiltrotor Propulsion System for an Aircraft - A method for operating a propulsion system of an aircraft includes moving a plurality of forward and aft propulsors to a vertical thrust position. While in the vertical thrust positions, the method also includes providing a first forward to aft ratio of electric power to the plurality of forward and aft propulsors. The method also includes moving the plurality of forward and aft propulsors to a forward thrust position. While in the forward thrust positions, the method also includes providing a second forward to aft ratio of electric power to the plurality of forward and aft propulsors. The first forward to aft ratio of electric power is different than the second forward to aft ratio of electric power to provide certain efficiencies for the aircraft. | 2020-03-19 |
20200085989 | AIR PURIFICATION SYSTEM - This invention relates to an air purification apparatuses and methods for air purification. The air purification apparatuses pass air through energy beams that form one or more fields of energy within a chamber to produce an outflow of sterilized air. In some aspects, a charge generation system is implemented to repel particles from the chamber walls. In some aspects, the fields of energy extend across substantially an entirety of the cross sectional area of the interior volume of the chamber and longitudinally within the chamber. In some aspects, a controller is configured to rotate a beam of collimated light energy within the chamber at a rotational velocity corresponding to at least V/W, wherein V is the linear velocity of a particle within the chamber along the longitudinal axis, and W is the width of the beam of collimated light energy. | 2020-03-19 |
20200085990 | CHEMILUMINESCENT WETNESS INDICATOR FOR ABSORBENT PRODUCTS - Disclosed herein are materials and structural elements for absorbent articles that incorporate at least one component of a chemiluminescent system configured to produce light upon contact with an aqueous system. This disclosure also relates to absorbent articles that incorporate materials or structural elements. This disclosure also relates to formulations and methods for treating materials or structural elements with one or more components of such a chemiluminescent system. Representative absorbent articles include disposable diapers and adult incontinence products. Representative chemiluminescent systems include bioluminescent systems. | 2020-03-19 |
20200085991 | WOUND DRESSING MATERIALS INCORPORATING ANTHOCYANINS DERIVED FROM FRUIT OR VEGETABLE SOURCES - A wound dressing composition, such as gauze, bandages, and surgical tapes comprising a substrate material impregnated with a pH sensitive dye composition comprising at least one anthocyanin derived from fruit or vegetable sources, and methods of use thereof. | 2020-03-19 |
20200085992 | WOUND DRESSING LAYER FOR IMPROVED FLUID REMOVAL - Disclosed herein are embodiments of a wound dressing layer. The wound dressing layer may include an open-cell foam. The foam may have a 50% compression force deflection of not more than about 4.8 kPa. The foam may also have a density of at least 24 kg/m | 2020-03-19 |
20200085993 | ABSORBENT, BREATHABLE AND PATHOGEN BLOCKING/KILLING WOUND CARE DRESSING AND FABRICATION THEREOF - This invention relates to a multi-layer wound site dressing specifically designed to treat chronic wounds and simultaneously block external pathogens from infecting the wound site from the environment. The said wound dressing comprises five layers; each layer performs a specific functionality in healing and protecting the wound site. The said layers of wound care dressing comprise (i) a permeable non-adherent woven or non-woven membrane in contact with wound site, (ii) a nanofibrous composite layer made of superabsorbent, activated carbon and a polymer (iii) a hydrophobic insulating membrane which is permeable to air with an adhesive edge, (iv) a nanofibrous membrane made of polymer and activated carbon hosting functional germicidal ions, and (v) an air permeable non-woven membrane with adhesive edge. The said layers are compounded by pressing and coating to make a comprehensive multi-layer wound care dressing product. | 2020-03-19 |
20200085994 | ABSORBENT ARTICLE COMPRISING A LOTION COMPOSITION FOR REDUCING ADHERENCE OF FECES OR MENSES TO THE SKIN - An absorbent article, intended to be worn by a wearer, wherein at least a part of a body facing surface of that article has a lotion composition. The lotion composition includes at least one first compound which is liquid at 25° C. and at least one second compound which is solid at 25° C. The first compound may be wax ester, and the second compound is a solid fatty compound selected from the group consisting of solid fatty acids, solid fatty alcohol and solid fatty soaps. When the solid fatty compound is a solid fatty acid, then the total amount of liquids is higher than the total amount of solids. | 2020-03-19 |
20200085995 | SYSTEM FOR SUTURELESS CLOSURE OF SCLERAL PERFORATIONS AND OTHER OCULAR TISSUE DISCONTINUITIES - The present disclosure describes, among other things, a thereto-responsive hydrogel comprising a PNIPAM copolymer having adhesive properties that are temperature dependent, as well as a device for administering the hydrogel, and methods for making and using the foregoing. | 2020-03-19 |
20200085996 | RESORBABLE MATERIAL DISPENSER AND METHOD OF USE - A method of stabilizing a craniomaxillofacial fracture includes heating a resorbable material to make the resorbable material flowable; applying the flowable resorbable material to a portion of a first bone fragment defining a fracture; and bonding the portion of the first bone fragment to an adjacent second bone fragment to stabilize the first bone fragment relative to the second bone fragment; wherein the first bone fragment is stabilized relative to the second bone fragment without an external force being applied directly to either the first bone fragment or the second bone fragment. | 2020-03-19 |
20200085997 | SYNTHETIC TISSUE GLUE - Compositions for use as a tissue glue or sealant are disclosed. The compositions include first and second precursor molecules, wherein the first precursor molecule is a polyoxyethylene-polyoxypropylene block copolymer having at least two nucleophilic groups and the second precursor molecule is a polyoxyethylene-polyoxypropylene block copolymer having at least two electrophilic groups. Biomaterials for use as a tissue glue or sealant, methods of making such biomaterials, devices for applying a biomaterial to a tissue of a patient, methods of sealing a tissue of a patient, and kits also are disclosed. | 2020-03-19 |
20200085998 | Meniscal Repair Adhesive - A composition that includes (a) a prepolymer having at least one free isocyanate group that is capable of bonding to tissue and that cures in vivo upon exposure to water to form a polymer having a compressive modulus between 1.9 and 14.4 MPa and a tensile modulus between 5.0 and 30, and (b) an oil that is miscible in the prepolymer, the oil being selected from the group consisting of silicone oils, mineral oil, vegetable oils, and combinations thereof. The composition retains its integrity when delivered in an aqueous medium. | 2020-03-19 |
20200085999 | IMPLANTABLE MEDICAL DEVICES WITH INCREASED IMMUNE TOLERANCE, AND METHODS FOR MAKING AND IMPLANTING - The present invention relates to the contacting of one or more surfaces of an implantable medical device with one or more diketopiperazines (DKPs). | 2020-03-19 |
20200086000 | COMBINATION GRAFTS FOR TISSUE REPAIR OR REGENERATION APPLICATIONS - The described invention provides soft tissue grafts, hard tissue grafts, and composite soft/hard tissue grafts and methods of producing such grafts. The grafts comprise a three-dimensional carrier matrix, a growth factor composition comprising an autologous platelet-rich fibrin and a cell culture composition comprising a culture medium, a population of cells suspended in the culture medium, and cells impregnated on or in a surface of osteoconductive particles. | 2020-03-19 |
20200086001 | SYSTEM AND METHODS FOR HARVESTING AND PROCESSING PERIOSTEUM FIBERS - Periosteum harvesting and processing systems and methods enable rapid, efficient, and repeatable harvesting of periosteum tissue from human long bones and processing of the tissue into individual fibers for use in strengthening surgical allograft products. One harvesting and processing method involves providing a human long bone, securing the long bone between two rotating live centers, scraping, using one of a plurality of harvesting tools selected from a harvesting and processing kit, periosteum tissue from the long bone, executing a first wash cycle comprising a hydrogen peroxide wash, executing a second wash cycle comprising an isopropyl alcohol wash, executing a third wash cycle comprising a phosphate buffered saline wash, compressing the periosteum tissue to remove excess fluid, cryofracturing the tissue until a desired fiber size is achieved, and separating the periosteum tissue into individual periosteum fibers having the desired fiber size. Other embodiments are also disclosed. | 2020-03-19 |
20200086002 | BIOVESSELS FOR USE IN TISSUE ENGINEERING - Described herein are bioengineered constructs and methods of producing the same. The constructs and methods disclosed herein can be applied towards, for example, the generation of vascular grafts to treat cardiovascular disease. | 2020-03-19 |
20200086003 | METHOD FOR DECELLULARIZATION OF SKIN TISSUE, METHOD FOR CONSTRUCTION OF ARTIFICIAL SKIN, METHOD FOR PREPARATION OF HYDROGEL OF DECELLULARIZED SKIN TISSUE, LYOPHILIZED, DECELLULARIZED SKIN TISSUE, AND BIOINK - A method for decellularization of a skin tissue according to an embodiment of the present invention comprises: a step of preparing a skin tissue to be decellularized; a peeling preparation step of treating the skin tissue with a first solution containing trypsin; and a peeling step of removing subcutaneous fat from the skin tissue after the peeling preparation step. | 2020-03-19 |
20200086004 | METHODS OF MAKING CELLULAR COMPOSITIONS DERIVED FROM DECEASED DONORS TO PROMOTE GRAFT TOLERANCE - The invention provides cellular compositions that contain CD34 | 2020-03-19 |
20200086005 | NEOCARTILAGE CONSTRUCTS USING UNIVERSAL CELLS - The invention relates to implantable systems for repairing and restoring cartilage. The invention provides methods and products for cartilage repair that use universal chondrocytes. A universal cell line includes cells such as universal chondrocytes that are not immunogenic or allergenic and can be grown in products suitable for use in a number of different people. Use of the universal chondrocytes allows for new processes and products. Where prior art autologous neocartilage constructs required many small reactors (e.g., at least one culture dish per patient to grow one 34 mm disc per patient), using a universal cell line allows, for example, one large batch of cartilage or neocartilage to be made under uniform conditions. | 2020-03-19 |
20200086006 | CELLULAR COMPOSITIONS DERIVED FROM DECEASED DONORS TO PROMOTE GRAFT TOLERANCE AND MANUFACTURE AND USES THEREOF - The invention provides cellular compositions that contain CD | 2020-03-19 |
20200086007 | GENERATING ARTERIAL ENDOTHELIAL CELL-SEEDED VASCULAR GRAFTS - Provided herein are human arterial endothelial cell-seeded polymeric vascular grafts suitable for replacing or bypassing natural blood vessels and exhibiting increased long term patency rates and reduced leukocyte adhesion relative to grafts comprising venous endothelial cells. Methods for generating the human arterial endothelial cell-seeded vascular grafts and therapeutic uses of the same are also described. | 2020-03-19 |
20200086008 | DEVICE HAVING A SWITCHABLE WET-DRY LUBRICATING COATING - A lubricating coating including at least one polymer A, a cross-linker and at least one lubricating agent, and wherein a portion of the at least two reactive groups of the cross-linker are covalently linked to the polymer A to form a three-dimensional network in which the lubricant is incorporated, and wherein at the same time another portion of the reactive groups of the cross-linker are covalently linked to the surface of the device or to the optional adhesion layer on the surface of the device. | 2020-03-19 |
20200086009 | HYALURONIC ACID-BASED GELS INCLUDING LIDOCAINE - Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided. | 2020-03-19 |
20200086010 | SYSTEMS AND METHODS FOR BIOFILM INOCULATION - Systems and methods for biofilm inoculation including a feeding tube having a distal end for placement in the gut of a patient, and a biofilm coated or otherwise provided on the distal end of the feeding tube for introducing the biofilm to the gut of the patient. In example embodiments, the biofilm can be colostrum, breast milk or one or more probiotics. | 2020-03-19 |
20200086011 | VASCULAR PROSTHESIS FOR LEAK PREVENTION DURING ENDOVASCULAR ANEURYSM REPAIR - An embodiment includes a process for treating an abdominal aortic aneurysm (AAA) endoleak with a shape memory polymer (SMP) foam device. First, a bifurcated stent graft is placed within the aneurysm while a micro guidewire is positioned within the aneurysm for future catheter access. Second, after placing the iliac graft extension, a catheter is introduced over wire to deliver embolic foams. Third, embolic foams expand and conform to the aneurysm wall. Fourth, embolic foams create a stable thrombus to prevent endoleak formation by isolating peripheral vessels from the aneurysm volume. | 2020-03-19 |
20200086012 | COMPOUND HEPARIN ANTICOAGULANT COATING LIQUID, A MICROSPHERE FOR COATING AND ITS PREPARATION METHODS AND APPLICATIONS - The present invention discloses a compound heparin anticoagulant coating liquid, a microsphere for coating and its preparation methods and applications. In the present invention, the combination of curcumin and heparin can enhance the anticoagulation functions of heparin coating, and further enhance the stability using the properties of PLA-PEG-PLA drug-loaded sustained-release microspheres, achieving the functions of anti-tissue proliferation and anti-inflammatory reactions that cannot be achieved by coatings alone such as heparin or protein, which is very important for implanted devices such as artificial blood vessels, vascular stents and vascular patches to reduce thrombosis in the human body, lower postoperative complications and improve product lifespan. | 2020-03-19 |
20200086013 | REDUNDANT CONTROLS FOR NEGATIVE PRESSURE WOUND THERAPY SYSTEMS - Embodiments of negative pressure wound therapy systems and methods are disclosed. In one embodiment, a system includes a wound dressing, negative pressure source, switch, and control circuitry. The switch can include an actuator that toggles states of first and second pairs of contacts in response to a user input. The control circuitry can supply negative pressure with the negative pressure source when the state of the first pair of contacts is a first state and the state of the second pair of contacts is a second state, and the control circuitry can disable supply of negative pressure with the negative pressure source when the state of the first pair of contacts is not the first state or the state of the second pair of contacts is not the second state. | 2020-03-19 |
20200086014 | NEGATIVE PRESSURE WOUND THERAPY SYSTEM - A negative pressure wound therapy system includes a dressing, a tube, a flow restriction pad, and an in-line filter. The dressing is configured for placement in a wound bed. The tube includes a first end and a second end. The first end is configured to be operably coupled to the dressing. The second end is configured to engage a negative pressure source. The flow restriction pad is configured to be coupled to the dressing proximate the first end of the tube. The flow restriction pad includes a tortuous fluid flow path that is configured to restrict or reduce an amount of a fluid drawn from the dressing into the tube and induce a backpressure between the dressing and the tube. The in-line filter is positioned within the tube between the first end and the second end. The in-line filter configured to substantially prevent the fluid entering the tube. | 2020-03-19 |
20200086015 | FLUID INGRESS PROTECTION FOR NPWT DEVICE - A negative pressure wound treatment (NPWT) system including a NWPT therapy unit and a wound dressing configured to overlay a wound bed. The NPWT system includes a first length of tubing comprising a first end and a second end, the first end of the first length of tubing coupled to the NWPT therapy unit and the second end of the first length of tubing having a first coupling half, as well as a second length of tubing having a first end and second end, the first end of the second length of tubing coupled to the wound dressing and the second end of the second length of tubing having a second coupling half. The NPWT system includes an inline filter comprising a sintered polymer and a superabsorbent material, and an inline coupling, wherein the inline coupling is configured to operably couple and de-couple the NPWT therapy unit and wound dressing. | 2020-03-19 |
20200086016 | FLUID COMMUNICATION PATH - An apparatus and method are disclosed for providing a fluid communication path to a wound site through a drape. The apparatus comprises a body portion having a lower surface and an upper surface, at least one connection port, at least one suction port and at least one fluid communication passageway between the connection port and the suction port. A connector at an end of at least one tubular conduit is locatable through the drape into an orifice in the connection port to thereby provide a fluid communication path through the drape between the tubular conduit and the wound site. | 2020-03-19 |
20200086017 | TUBING CONNECTION SYSTEM FOR NEGATIVE PRESSURE WOUND THERAPY - A resilient connector for a negative pressure wound therapy system. The connector includes a first lumen having an entrance dimensioned and configured for slidably engaging a projection of a canister adapter to provide fluid communication of the first lumen to a first portion of reduced pressure tubing and an exit dimensioned and configured for slidably engaging a first projection of a dressing adapter to provide fluid communication of the first lumen to a second portion of reduced pressure tubing. The connector further a second lumen having an entrance dimensioned and configured for slidably engaging a second projection of the canister adapter to provide fluid communication of the second lumen to a first portion of secondary pressure tubing and an exit dimensioned and configured for slidably engaging a second projection of the dressing adapter to provide fluid communication of the second lumen to a second portion of the secondary pressure tubing. | 2020-03-19 |
20200086018 | Connector with Valve for Negative Pressure Wound Therapy System - A negative pressure wound therapy device that includes a first tubing connectable in flow communication with a source of negative pressure configured for application of negative pressure to a wound site, a second tubing in flow communication with the wound site, and a valve. | 2020-03-19 |
20200086019 | MANUAL BREAST PUMP AND METHOD OF USE - A manual breast pump is disclosed. The manual breast pump comprises a breast cup configured to engage with a mother's breast and a reservoir at a base of the breast cup configured to collect milk extracted from the mother's breast. The reservoir is defined by a wall. The wall comprises a varying thickness from a top of the reservoir toward a bottom of the reservoir. | 2020-03-19 |
20200086020 | EXPRESSION KIT FOR A BREAST PUMP DEVICE - An expression kit ( | 2020-03-19 |
20200086021 | INTRODUCER ASSEMBLY AND METHOD OF USE THEREOF - The invention provides an introducer assembly for delivering a blood pump into vasculature of a subject, as well as a method for utilizing the assembly. | 2020-03-19 |
20200086022 | SYSTEMS AND METHODS FOR DETERMINING CARDIAC PERFORMANCE - The systems and methods described herein determine metrics of cardiac performance via a mechanical circulatory support device and use the cardiac performance to calibrate, control and deliver mechanical circulatory support for the heart. The systems include a controller configured to operate the device, receive inputs indicative of device operating conditions and hemodynamic parameters, and determine vascular performance, including vascular resistance and compliance, and native cardiac output. The systems and methods operate by using the mechanical circulatory support device (e.g., a heart pump) to introduce controlled perturbations of the vascular system and, in response, determine heart parameters such as stroke volume, vascular resistance and compliance, left ventricular end diastolic pressure, and ultimately determine native cardiac output. | 2020-03-19 |
20200086023 | METHOD OF STARTING A BLOOD PUMP WITH AN ELECTRICAL FAULT - A method of starting an implantable blood pump including a first stator and a second stator, the method including detecting an electrical fault in one of a group consisting of the first stator and the second stator and commencing a startup of the first stator and the second stator in response to the electrical fault. | 2020-03-19 |
20200086024 | SYSTEMS AND METHODS FOR INCREASING CONVECTIVE CLEARANCE OF UNDESIRED PARTICLES IN A MICROFLUIDIC DEVICE - A microfluidic device for increasing convective clearance of particles from a fluid is provided. A network of first channels can be separated from a network of second channels by a first membrane. The network of first channels can also be separated from a network of third channels by a second membrane. Fluid containing an analyte can be introduced in the network of first channels. Infusate can be introduced into the network of second channels, and waste-collecting fluid can be introduced into the network of third channels. A pressure gradient can be applied in a direction perpendicular to the direction of fluid flow in the network of first channels, such that the analyte is transported from the network of first channels into the network of third channels through the second membrane. | 2020-03-19 |
20200086025 | SAFE CONTROL OF DIALYSIS MACHINES USING A REMOTE CONTROL DEVICE - A communication connection between a dialysis machine (such as a hemodialysis machine or a peritoneal dialysis machine) and a control device located away from the dialysis machine may be secured based on a safety protocol being implemented. The safety protocol may be executed in a server-side integrated circuit component and in a client-side integrated circuit component. | 2020-03-19 |
20200086026 | TECHNIQUES FOR DIALYSIS BASED ON RELATIVE BLOOD VOLUME - Systems, methods, and/or apparatuses may be operative to perform a dialysis process using RBV-based UF control. Embodiments may include methods operative to receive RBV target information comprising population-based dialysis data of real patient outcomes of a patient population associated with the patient, determine an RBV value of a patient during the dialysis process, and determine UF information to control a UF pump of the dialysis device to maintain the RBV value within a target RBV range defined by the RBV target information. Other embodiments are described. | 2020-03-19 |
20200086027 | ABSOLUTE BLOOD VOLUME ESTIMATION DEVICE AND METHOD - Absolute blood volume in dialysis patients is a useful patient attribute to know for dialysis treatment, diagnosis, adjustments, etc. In some cases, it is difficult or impossible to directly determine absolute blood volume. Estimating absolute blood volume may be used to overcome the inability to directly determine the absolute blood volume. Estimating absolute blood volume may include obtaining a series of measurements of hemoconcentration of a patient over a time period, and estimating parameters for a physiological model based on the series of measurements. The absolute blood volume of the patient may be determined using the physiological model. | 2020-03-19 |
20200086028 | PERITONEAL DIALYSIS PATIENT LINE WITH STERILIZING FILTER AND DRAIN BYPASS - A medical fluid treatment system includes a source of purified water; at least one concentrate for mixing with the water from the source to form a treatment fluid; a disposable set including a pumping portion, a concentrate line in fluid communication with the concentrate source and the pumping portion, and a patient line in fluid communication with the pumping portion, the patient line including a filter having a membrane configured to filter the treatment fluid, the filter configured such that (i) fresh treatment fluid flowing from the pumping portion towards a patient flows through the membrane and (ii) used treatment fluid flowing through the filter from the patient to the pumping portion bypasses the membrane; and a medical fluid delivery machine including a pump actuator operable with the pumping portion of the disposable set. | 2020-03-19 |
20200086029 | SECURE INPUT ON A CONTROL COMPONENT FOR A DIALYSIS MACHINE - A medical device, such as a hemodialysis machine or a peritoneal dialysis machine, is provided with control commands in a secure manner based on the commands being detected on a separate control component. The control commands are detected and thereupon a message is generated which contains a request to activate an operating element. Only if the indicated operating element has been activated is the control command forwarded to a dialysis machine for execution. | 2020-03-19 |
20200086030 | MEDICAL TREATMENT SYSTEM AND METHODS USING A PLURALITY OF FLUID LINES - A medical treatment system, such as peritoneal dialysis system, may include control and other features to enhance patient comfort and ease of use. For example, a peritoneal dialysis system may include patient line state detector for detecting whether a patient line is primed before it is to be connected to the patient. The patient line state detector can also the ability to detect whether a patient line has been properly mounted for priming. Both patient line presence/absence and fill state can be determined using an optical system, e.g., one that employs a single optical sensor. | 2020-03-19 |
20200086031 | FLUID PUMPING DEVICE AND BLOOD PURIFYING APPARATUS HAVING THE SAME - Provided is a blood purifying apparatus including a blood purifying filter in which mass transfer occurs between blood and dialysis fluid, a blood tube connecting the blood purifying filter and a patient to allow blood to flow therethrough, a dialysis fluid supply tube connected to the blood purifying filter and allowing dialysis fluid to be supplied to the blood purifying filter therethrough, a dialysis fluid discharge tube connected to the blood purifying filter and allowing dialysis fluid to be discharged from the blood purifying filter therethrough; and a fluid pumping device. The fluid pumping device further includes a plurality of chamber each having an internal space, a chamber pressurizing member disposed inside the plurality of chambers and compressing or expanding the chambers to thereby allow a fluid to flow therethrough, and a flow controller controlling a flow passage. | 2020-03-19 |
20200086032 | METHOD OF TREATING TRAUMATIC BRAIN INJURY - The present invention concerns methods of treating a patient suffering from a traumatic brain injury (TBI), comprising contacting said patient's blood with a sorbent for an inflammatory mediator and kits for performing such treatments. | 2020-03-19 |
20200086033 | SYSTEM AND METHOD FOR EXTRACORPOREAL TEMPERATURE CONTROL - Improved systems and methods for extracorporeal blood temperature control and patient temperature control, e.g., for induced hypothermia and optional normothermia, may include or otherwise employ a heat exchanger for cooling/warming of a fluid, a thermal exchange module having fluidly-isolated first and second volumes, and a fluid pump for circulating the fluid through the heat exchanger and the first volume of the thermal exchange module. A blood pump may be provided for the flow of blood through the second volume of the thermal exchange module, and a first controller may be provided for providing output signals for use in operation of the heat exchanger to selectively control thermal exchange between the fluid circulated through the first volume of the thermal exchange module and the blood flowed through the second volume of the thermal exchange module, thereby providing for selective cooling/warming of the blood. A multi-lumen catheter may be utilized for the flow of blood from a patient vascular system to the second volume of the thermal exchange module, and for flow of blood from the second volume of the thermal exchange module back to the patient vascular system. The circulated fluid may be optionally circulated through a patient contact pad(s) for contact cooling/warming, wherein patient cooling/warming may be provided in a first mode via blood cooling/warming in the thermal exchange module, and patient cooling/warming may be provided in a second mode via thermal exchange by the contact pad(s). | 2020-03-19 |
20200086034 | FLOW CONTROL SYSTEM - A control system is provided to restrict the flow rate of blood in a venous line | 2020-03-19 |
20200086035 | HEMODIALYSIS SYSTEMS AND METHODS - Hemodialysis systems are described. A hemodialysis system may include a dialysate flow path through which dialysate is passed from a dialysate reservoir, which includes a valved vent to atmosphere, to an ultrafilter. The dialysate flow path includes a pneumatically actuated diaphragm-based dialysate pump for pumping fluid from the dialysate reservoir to the ultrafilter. The hemodialysis system may include a controller for controlling pneumatic actuation pressure delivered to the dialysate pump and at least one valve connecting the dialysate reservoir vent to the atmosphere. The hemodialysis system may be configured to actuate the dialysate pump and the at least one valve to introduce air into the dialysate flow path and expel liquid from the dialysate flow path to a drain. | 2020-03-19 |
20200086036 | AN INFUSION SYSTEM FOR SHORT-LIVED RADIOPHARMACEUTICALS - A non-surgical method of delivering a liquid radioactive solution from a source to a recipient comprising the steps of: determining a desired recipient level of radioactivity and recipient volume of the radioactive solution to be delivered to the recipient, providing a first valve having a waste position and a recipient position, providing a bolus conduit, a waste conduit and a recipient conduit, each conduit having a valve end being connected to said first valve, so that the first valve can establish a waste flow path in the waste position and a recipient flow path in the recipient position, the recipient flow path being different from said waste flow path, the bolus conduit comprising a measuring section and an internal volume, the internal volume being approximately equal to the desired recipient volume of the radioactive solution to be delivered to the recipient, arranging said first valve in the waste position, transporting a first amount of said radioactive solution through said waste flow path, the first amount of said radioactive solution having an initial level of radioactivity that is at least approximately equal to or higher than the desired recipient level of radioactivity and an initial volume that is larger than the internal volume of said bolus conduit, providing a radiation detector, the radiation detector being operable to measure a level of radioactivity of the radioactive solution in said measuring section, measuring a reference level of radioactivity of said radioactive solution present in said measuring section, wherein when the reference level of radioactivity is approximately equal to an injection level of radioactivity, the method further comprises the steps of: arranging the first valve in the recipient position, and transporting the radioactive solution present in the bolus conduit through the recipient flow path. | 2020-03-19 |
20200086037 | INLINE MICROGRAVITY AIR TRAP DEVICE AND AN INTRAVENOUS ASSEMBLY INCORPORATING AN INLINE MICROGRAVITY AIR TRAP DEVICE - An inline microgravity air trap device includes an elongate air trap chamber, the air trap chamber having a blind end, an opposite air outlet end containing a gas egress opening, a fluid inlet port connecting to a pressurized fluid supply, a fluid outlet port connecting the air trap chamber to a fluid delivery destination, a filter forming a tube having an interior, a first end at the blind end of the air trap chamber and a second end at the gas egress opening, and a structural insert in the interior of the tube, having a first insert end located at the blind end, and a second insert end located the air outlet end, where the chamber is formed to direct fluid from the pressurized fluid supply to accelerate centrifugally around the filter, forcing gas contained in the fluid to pass through the filter into the interior of the tube. | 2020-03-19 |
20200086038 | CAP AND METHODS OF MAKING AND USING SAME - The present disclosure is directed to a cap to be worn by an individual having a scalp intravenous tube so as to help in maintaining the body temperature of the individual. The cap includes a body, at least one opening and a fastener. The body has a plurality of panels. The at least one opening is formed between the plurality of panels of the body. The fastener is positioned on a portion of at least one of the plurality of panels of the body to connect the plurality of panels of the body so as to attach the body of the cap to a head of an individual. | 2020-03-19 |
20200086039 | Hydraulically Actuated Pump for Fluid Administration - A fluid delivery device comprises a hydraulic pump chamber having a hydraulic fluid. A fluid reservoir is coupled to the hydraulic pump chamber and is configured to contain a fluid deliverable to a patient. A first actuator is coupled to the hydraulic pump chamber and is configured to pressurize the hydraulic pump chamber and configured to transfer energy through the hydraulic pump chamber to the fluid reservoir. A second actuator is coupled to the hydraulic pump chamber and is configured to pressurize the hydraulic pump chamber and configured to transfer energy through the hydraulic pump chamber to the fluid reservoir. | 2020-03-19 |
20200086040 | INFUSION PUMP ASSEMBLY - An infusion pump assembly includes a locking tab and a pump barrel inside a pump barrel housing, where the pump barrel accommodates a reservoir assembly. The reservoir assembly includes a reservoir and a plunger rod. The infusion pump assembly also includes a locking disc at a terminus of the pump barrel. The locking disc includes a clearance hole for the plunger rod. The locking disc also includes at least one locking tab notch in close proximity with the locking tab. The locking tab is in moveable engagement with the locking tab notch, and the reservoir moves the locking tab from a locked position to an unlocked position when the plunger rod is inserted through clearance hole. The locking disc rotates upon torque being applied to the reservoir assembly, the locking disc rotating from a non-loaded position to a loaded position with respect to the plunger rod and a drive screw. | 2020-03-19 |
20200086041 | STERILE PUMP MODULE FOR AN INFUSION PUMP - A pump module for an infusion pump includes a plunger-cylinder unit that can be coupled to the infusion pump in order to deliver fluid from a fluid feed line into a fluid drain line to a patient. The plunger-cylinder unit has a delivery chamber that is fluidically connected to the fluid feed line and the fluid drain line. The delivery chamber is delimited by the cylinder ( | 2020-03-19 |
20200086042 | Apparatus, Systems and Methods for an Infusion Pump Assembly - A system for delivery of a volume of infusible fluid. The system includes a controller configured to calculate a trajectory for delivering infusible fluid, the trajectory comprising at least one volume of fluid, and determine a schedule for delivering the at least one volume of fluid according to the trajectory, wherein the schedule comprising an interval and a volume of infusible fluid for delivery. The system also includes a volume sensor assembly for determining the at least one volume of fluid delivered, wherein the controller recalculates the trajectory based on the volume of fluid delivered. | 2020-03-19 |
20200086043 | METHOD AND DEVICE UTILIZING MEDICAMENT DELIVERY PROTOCOLS - A device for infusing liquid medicaments such as insulin includes an infusion pump. The device can modify a medicament delivery protocol stored in memory to delivery an alternative medicament delivery protocol with the pump. | 2020-03-19 |
20200086044 | Patch Pump - A disposable module that can be coupled to a reusable module in order to form a pump for dispensing a medicament substance to a user in a metered manner in a coupled state, comprising a housing that encases the following components: a reservoir for receiving the substance to be dispensed; and at least one extensible cannula, which is fluidically connected to the reservoir either after being inserted or in a permanent manner. The disposable module may also comprise an electrical energy store, wherein the electrical energy necessary for the reusable module can be obtained both from the disposable module and also from a rechargeable battery in the reusable module, in order to ensure redundancy of the energy necessary for the reusable module. | 2020-03-19 |
20200086045 | INFUSION PUMP LATCH MECHANISM AND ASSOCIATED FREE-FLOW PROTECTION DEVICE - An infusion pump apparatus includes a length of resilient tubing removably loadable in an infusion pump having a housing, a pumping mechanism, and a pump door. A latch member is pivotally mounted to the pump door and cooperates with a latch pin fixed on pump housing. A free-flow protection device is biased to pinch the tubing closed to stop fluid flow. The latch member has a first range of pivotal motion in a latching direction for causing the latch member to engage with the latch pin to secure the door in a closed position and a second range of pivotal motion in the latching direction for causing the latch member to actuate the free-flow protection device to unpinch the tubing and allow flow. The latch member pivots through at least a portion of the first range of pivotal motion before beginning to pivot through the second range of pivotal motion. | 2020-03-19 |
20200086046 | REPORTING SYRINGE - A reporting syringe, including a barrel in fluid communication with a needle connected with a first end of the barrel, a piston including a plunger, the piston positioned within a second end of the barrel and the plunger having a fluid-tight interaction with an interior of the barrel, and a microprocessor in electronic communication with a switch and a wireless module, the microprocessor configured to send an administration completion data from the wireless module after triggering the switch. | 2020-03-19 |
20200086047 | PATIENT STIMULATION SYSTEM - A stimulation system for treating a patient comprises: a stimulator comprising at least one stimulation element for delivering stimulation to the patient, the delivered stimulation based on a set of stimulation settings; a controller for adjusting a stimulation setting of the stimulator; and a diagnostic device for measuring a physiologic response to the test stimulation on the patient. The set of stimulation settings comprise a set of test stimulation settings and a set of therapeutic stimulation settings. The stimulation comprises test stimulation delivered to the patient for a test duration, and therapeutic stimulation delivered to the patient for an extended duration. The test stimulation is based on the set of test stimulation settings and the therapeutic stimulation is based on the set of therapeutic stimulation settings. The set of therapeutic stimulation settings is based on an assessment of the measured physiologic response. Methods of delivering stimulation are also provided. | 2020-03-19 |
20200086048 | PORTAL SYSTEM-BASED BIONIC PANCREAS - Embodiments include methods and systems for maintaining glucose homeostasis. Systems can include a pump, a first reservoir including a homeostasis agent, an umbilical catheter capable of being advanced in the umbilical vein or in the falciform ligament, and a sensor. Systems can also include a biocompatible coating, a microprocessor in communication with the pump and the sensor, and a power supply. Methods can include implanting a pump and reservoir subcutaneously in a patient, advancing a catheter in the umbilical vein or in the falciform ligament, measuring a blood glucose level, pumping a homeostasis agent, and administering the homeostasis agent to the portal venous system. | 2020-03-19 |
20200086049 | Kit For Treating or Relieving Pain at Incision Site Following Surgical Procedure - The present in relates to a kit for treating or relieving incision site pain. According to the present invention, there is provided a kit for treating or relieving postoperative incision site pain, which makes effective treatment possible by injecting a pain relief drug or a treatment drug into a surgical site in situ after incisional surgery during an incisional surgical procedure, and stably and slowly releasing the drug. | 2020-03-19 |
20200086050 | INJECTION DEVICE WITH DELIVER PHASE VELOCITY REGULATOR - Disclosed is an injection device for delivering a medicament from a syringe contained within a housing, the device being configured to move the syringe through the housing to cause insertion of a needle of the syringe into a user's skin and move a syringe bung through a syringe body, delivering medicament through the needle. The device includes: a plunger engaging the bung; a sleeve around the plunger; an insertion spring biasing the sleeve to the housing; and a delivery spring biasing the plunger to the sleeve. A release mechanism releases the sleeve from the housing to commence insertion and release the plunger from the sleeve, following insertion, delivering medicament. A velocity regulator regulates the plunger upon release and disengages during delivery, and includes a screw thread associated with the sleeve or plunger and one or more thread engaging members formed on the other of the sleeve and the plunger. | 2020-03-19 |
20200086051 | AUTO-INJECTOR - An injection device includes a carrier, a needle, a driver coupled to the needle, the driver being slidable relative to the carrier between a retracted configuration and a deployed configuration, a shuttle configured to move the driver between the retracted configuration and the deployed configuration, and a stop configured to move from a first configuration to a second configuration, wherein the stop is configured to maintain the driver in the deployed configuration, and movement of the stop from the first configuration to the second configuration allows the shuttle to move the driver from the deployed configuration to the retracted configuration. | 2020-03-19 |
20200086052 | CAP ASSEMBLY WITH CARTRIDGE - A cap assembly adapted to be attached to a drug delivery device main unit, comprising a drug-filled cartridge with an axially moveable piston and a distal portion with a needle penetratable seal, a needle assembly and a cap. The needle assembly comprises a needle having a distal skin-piercing end and a proximal seal-piercing end. The cap comprises a reservoir adapted to receive the needle distal end, the cap accommodating the needle assembly and at least the distal portion of the cartridge. The needle assembly and the cartridge are arranged axially moveable relative to each other between an initial state in which the proximal needle end is arranged distally of the cartridge seal, and an operational state in which the proximal needle end has penetrated the cartridge seal, wherein the reservoir is adapted to receive drug from the cartridge via the needle. | 2020-03-19 |
20200086053 | INJECTION DEVICE - Disclosed is an injection device for receiving a syringe therein and for delivering a dose of medicament from the syringe, the injection device including: an insertion driver configured to drive the syringe forwards within the injection device for inserting a needle of the syringe into an injection site; an interlock mechanism configured to retain the insertion driver in a primed state and, when actuated, to allow the insertion driver to drive the syringe forwards; and an interlock actuator moveable between a stowed position and an operable position and configured on movement from the stowed position to the operable position to couple to an actuation system such that movement from the operable position back towards the stowed position actuates the interlock mechanism. | 2020-03-19 |
20200086054 | COLD SLURRY SYRINGE - A cold slurry syringe with enhanced features is provided for delivering a cold slurry into the human body. The syringe includes a syringe body for holding a volume of cold slurry, a plunger that slides within the syringe body for ejecting the cold slurry, and a tapered syringe head for delivering an even flow of cold slurry. An agitator can be added to keep the cold slurry from agglomerating and clogging the syringe. Insulation added around the syringe can keep the cold slurry from melting too quickly. A ball screw drive can be added to provide a smooth and consistent application of pressure as the cold slurry is delivered. The cold slurry flow can be enhanced by adding a streamline flow feature that reduces the occurrence of eddies or swirls inside the syringe. This feature can also help maintain the composition and consistency of the cold slurry. | 2020-03-19 |